Clinical trials: Colorectal Cancer Liver Metastasis
Carcinoma, Hepatocellular, Colorectal Neoplasms
Early Biomarkers of Tumor Response in High Dose Hypofractionated Radiotherapy Word Package 3 : Immune Response
This study will follow-up immune cell populations, secreted factors and released nanovesicles in the blood before, during and after high dose radiation therapy which should give new information of the efficacy of the…
- Conditions
- Carcinoma, Hepatocellular, Colorectal Neoplasms, Melanoma, Kidney Neoplasms
- Trial name
- NCT02439008
- Testing
- Blood samples collection before radiotherapy, Blood samples collection during radiotherapy, Blood samples collection after radiotherapy
- Where
- France
- Volunteers
- 28 people
- Sponsor
- Centre Oscar Lambret
Hepatocellular Carcinoma, Hepatocellular Cancer
Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers
Background: A most common liver cancer in adults is hepatocellular carcinoma. Other kinds of liver cancer happen when colorectal or pancreatic cancer spreads to the liver.
- Conditions
- Hepatocellular Carcinoma, Hepatocellular Cancer, Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer
- Trial name
- NCT03785210
- Testing
- nivolumab, tadalafil, oral vancomycin
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- National Cancer Institute (NCI)
Liver Metastases, Liver Neoplasms
Non-Contrast Versus Contrast-Enhanced MRI in Colorectal Liver Metastases
This prospective study aims to compare the diagnostic performance of a non-contrast abbreviated MRI protocol with a contrast-enhanced MRI protocol for the detection and follow-up assessment of colorectal liver metastases.
- Trial name
- NCT07857317
- Volunteers
- 40 people
- Sponsor
- Assiut University
ColoRectal Cancer, Liver Metastasis Colon Cancer
COLLISION Trial - Colorectal Liver Metastases: Surgery vs Thermal Ablation
The primary objective is to prove non-inferiority of thermal ablation compared to hepatic resection in patients with at least one resectable and ablatable colorectal liver metastases (≤3cm) and no extrahepatic disease.
- Conditions
- ColoRectal Cancer, Liver Metastasis Colon Cancer, Liver Metastases, Surgery
- Trial name
- COLLISION (NCT03088150)
- Testing
- Thermal ablation, Surgical resection
- Where
- Netherlands
- Volunteers
- 618 people
- Sponsor
- Amsterdam UMC, location VUmc
Colorectal Neoplasms
Effect of TroVax in Patients Having Colorectal Cancer With Liver Metastases Removed
This study will test the safety and efficacy of TroVax in patients undergoing surgical resection of colorectal cancer with liver metastases.
- Trial name
- NCT00259844
- Testing
- TroVax
- Volunteers
- 20 people
- Sponsor
- Cancer Research UK
Metastatic Colorectal Carcinoma (mCRC), Metastatic Liver Cancer
Streamlining Radioembolization for CCC and Metastatic Liver Cancer
TARE uses radioactive microspheres (20-60 μm), which are trapped in tumors due to abnormal vasculature, while normal liver sinusoids (≤15 μm) prevent their passage.
- Conditions
- Metastatic Colorectal Carcinoma (mCRC), Metastatic Liver Cancer, Cholangiocarcinoma
- Trial name
- ISTAR-03 (NCT07043387)
- Where
- 4 sites in South Korea
- Volunteers
- 60 people
- Sponsor
- Seoul National University Hospital
Liver Neoplasms, Colonic Neoplasms
Safety, Efficacy, and Dosing of Stereotactic Radiosurgery for Hepato-cellular Carc/Colo-rectal Liver Metastases
The purpose of this study is to determine a tolerable dose of radiation delivered by the CyberKnife system in two groups of patients with hepatocellular carcinoma (HCC).
- Conditions
- Liver Neoplasms, Colonic Neoplasms, Metastatic Cancer to Liver
- Trial name
- NCT01528878
- Testing
- Stereotactic Radiosurgery using the CyberKnife System.
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Metastasis, Quality of Life
Health Related Quality of Life After Surgery and Oncological Treatment of Colorectal Liver Metastases
The purpose of this trial is to study health related quality of life (HQoL)after resection of colorectal liver metastases combined with perioperative chemotherapy.
- Trial name
- HQOL (NCT01587976)
- Where
- Norway
- Volunteers
- 100 people
- Sponsor
- Haukeland University Hospital
Colorectal Cancer, Colorectal Carcinoma
Elevated Platelet Count as Prognostic Factor in Colorectal Cancer With Synchronous Liver Metastases
Colorectal cancer (CRC) is the third most common malignancy worldwide and is often metastatic at diagnosis. Despite progresses in surgical techniques and the introduction of novel chemotherapy regimens, many patients still suffer…
- Conditions
- Colorectal Cancer, Colorectal Carcinoma, Stage IV Colon Cancer
- Trial name
- PLTCRC (NCT03717519)
- Testing
- Measurement of platelet count at diagnosis
- Where
- Italy
- Volunteers
- 196 people
- Sponsor
- Azienda Ospedaliera Universitaria Integrata Verona
Colorectal Cancer
Anlotinib Combined With Sintilimab as First-line Treatment for Advanced Non-liver Metastatic Colorectal Cancer
Colorectal cancer (CRC) is the third most common malignant tumor worldwide and the second leading cause of cancer-related deaths.
- Trial name
- NCT07398326
- Testing
- anlotinib and sintilimab
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Shanghai Changzheng Hospital
Primary Liver Cancer, Colorectal Cancer Liver Metastases
Multi-mode Ablation and Molecular Imaging Multi-omics Study for Digestive-Origin Malignant Liver Tumors
This single-center, parallel-controlled clinical trial aims to establish a multi-mode ablation system for liver malignant tumors originating from the digestive system.
- Trial name
- NCT06588569
- Testing
- Multi-mode tumor treatment system, Radiofrequency ablation therapeutic apparatus
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Fudan University
Colon Cancer, Synchronous Liver Metastases
QL1706 Combined With Standard Therapy for Conversion Therapy of Synchronous Liver Metastases From Colon Cancer: a Multicenter, Single-arm, Exploratory Study
This is a single-arm clinical study aiming to enroll 30 colon cancer patients with liver-only metastases. All eligible participants will undergo screening and enrollment after signing the informed consent form.
- Trial name
- NCT07649473
- Testing
- QL1706 (Iparomlimab/Tuvonralimab)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fujian Medical University
Liver Metastases, Colorectal Cancer
Comparison of Triphasic CT, PET and MR Tumour With Pathological Findings in Colorectal Cancer Liver Metastases
The purpose of this study is to correlate the MRI CT and PET appearances of colorectal liver metastases to pathologic appearance ot better understand the accuracy of imaging to determine tumor size.
- Trial name
- NCT00242086
- Testing
- CT, PET and MRI
- Where
- Canada
- Volunteers
- 7 people
- Sponsor
- University Health Network, Toronto
Colorectal Cancer
Fruquintinib Plus Camrelizumab and HAIC in the Treatment of Non-MSI-H Advanced Colorectal Cancer
Liver metastasis is the main cause of death in patients with colorectal cancer. The treatment of liver metastasis of colorectal cancer is the key to prolong the survival of patients.
- Trial name
- NCT06423937
- Testing
- combination therapy Combination: Fruquintinib plus Camrelizumab and HAIC (TOMOX/TOMIRI) Maintenance: Fruquintinib plus Camrelizumab
- Where
- China
- Volunteers
- 129 people
- Sponsor
- Fudan University
Colorectal Cancer
The Efficacy and Safety of Lcaritin Combined With Bevacizumab and FOLFIRI in Treatment of Liver Metastases From Colorectal Cancer
To evaluate the efficacy and safety of the combination regimen of Icaritin with bevacizumab + FOLFIRI in patients with liver metastases from advanced colorectal cancer.
- Trial name
- NCT06269445
- Testing
- Icaritin Combined With Bevacizumab and FOLFIRI
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Sir Run Run Shaw Hospital
Breast Cancer, Colon Cancer
Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer
This pilot clinical trial studies copper Cu 64 anti-carcinoembryonic antigen (CEA) monoclonal antibody M5A positron emission tomography (PET) in diagnosing patients with CEA positive cancer.
- Conditions
- Breast Cancer, Colon Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer
- Trial name
- NCT02293954
- Testing
- radionuclide imaging, positron emission tomography, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- City of Hope Medical Center
Liver Metastasis Colon Cancer, Colorectal Cancer
Liver Transplantation for Non-Resectable Colorectal Liver Metastasis
The study aims to evaluate the efficacy of liver transplantation in the context of non-resectable colorectal liver metastasis. The primary endpoint is the overall survival in this group of patients while the secondary endpoint is…
- Trial name
- NCT05185245
- Testing
- Liver Transplantation
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Colorectal Cancer Metastatic
Holmium-166 TARE in Liver Limited Unresectable Colorectal Cancer Patients
The aim of this study is to assess the efficacy of 166Ho-TARE followed by maintenance therapy with fluoropyrimidine and anti-EGFR or bevacizumab in liver-limited unresectable colorectal cancer patients, in terms of progression…
- Trial name
- HAITI (NCT06332079)
- Testing
- 166Holmium TARE, Cetuximab, Panitumumab
- Where
- Italy
- Volunteers
- 4 people
- Sponsor
- Gruppo Oncologico del Nord-Ovest
Colorectal Cancer
Cetuximab/FOLFIRI With or Without Oxaliplatin and FOLFOXIRI With or Without Bevacizumab in Neoadjuvant Treatment of Non-resectable Colorectal Liver Metastases
The aim of this study is to investigate the following schedules for efficacy with regard to response rate in neoadjuvant treatment of patients with non-resectable liver metastases: Cetuximab/FOLFOXIRI and cetuximab/FOLFIRI in…
- Trial name
- CELIM2 (NCT01802645)
- Testing
- Cetuximab, Bevacizumab, Irinotecan
- Where
- 15 sites in Germany
- Volunteers
- 91 people
- Sponsor
- Technische Universität Dresden
Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma
A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours
This first-in-human study evaluates safety, tolerability and distribution of [225Ac] FPI-1966, [111In]-FPI-1967, and vofatamab in patients with FGFR3-expressing solid tumors.
- Conditions
- Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma, Bladder Carcinoma, Susceptible FGFR3 Genetic Alterations
- Trial name
- NCT05363605
- Testing
- [225Ac]-FPI-1966, [111In]-FPI-1967, vofatamab
- Where
- 6 sites in United States, Australia
- Volunteers
- 6 people
- Sponsor
- Fusion Pharmaceuticals Inc.